Peter May
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter May has a total of 262 co-authors. Here are the top co-authors by number of shared publications:
- Charles Normand
Affiliation Centre for Health Policy and Management, Trinity College, the University of Dublin, Dublin, Ireland
24 shared publications Charles Normand
King’s College London
10 shared publicationsR. Sean Morrison
Icahn School of Medicine at Mount Sinai, New York, NY
10 shared publications- Rose Anne Kenny
Trinity College Dublin
10 shared publications J. Brian Cassel
Massey Cancer Center, Virginia Commonwealth University, Richmond, USA
9 shared publicationsSoraya Matthews
Centre for Health Policy and Management, School of Medicine, Trinity College Dublin, Dublin, Ireland
7 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by SAGE Publications in Palliative Care and Social Practice
- Vol. 20
Characteristics of older people who experience high-cost hospital care at the end of life and report low-satisfaction: Evidence of low-value care from bereaved carer surveys in England
Background: A significant proportion of healthcare costs is incurred in hospitals at the end of life (EoL), with a small group of patients accounting for most of the costs. Scarce resources should be allocated based on cost-effectiveness. High costs and low satisfaction with care suggest low-value care at EoL; however, there is little evidence regarding which patients receive such care. Objectives: To identify the characteristics of older patients who experience high-cost care but report low satisfaction with care at EoL. Design and methods: Secondary data analysis of mortality follow-back surveys: International Access, Rights, and Empowerment (IARE) studies. We surveyed the next of kin of older patients who received palliative care or died in hospital in England. Satisfaction with care at EoL and cost of hospital care calculated with quantity of services and unit costs. We used multinomial logistic regression to analyse factors associated with potentially low-value care. Results: 404 patients were included (mean [SD] age: 80.4 [8.5] years). During the last three months of life, 53.8% of the total hospital care costs were incurred by 20% of the patients. 36.6% of the respondents reported low satisfaction. Compared to patients with low-cost care and reporting satisfaction, patients who were 65-74 years old (relative risk ratio [RRR] = 3.2, 95% CI: 1.09 to 9.42), had low income (RRR = 4.12, 95% CI: 1.29 to 13.15) and with an illness duration of 1-12 months (RRR = 3.93, 95% CI: 1.37 to 11.21) were more likely to receive high-cost hospital care and report low satisfaction. Conclusions: Being younger, on low incomes and with short illness duration are associated with high-cost, low-satisfaction hospital care at EoL. Identifying underlying mechanisms may enable targeted interventions to reduce high-cost, low-value care. Further investigation is needed to change the care trajectories of patients with these risk factors.
- 28 July 2026
- Published by SAGE Publications in Palliative Care and Social Practice
- Vol. 20
Open AccessCharacteristics of older people who experience high-cost hospital care at the end of life and report low-satisfaction: Evidence of low-value care from bereaved carer surveys in England
Background: A significant proportion of healthcare costs is incurred in hospitals at the end of life (EoL), with a small group of patients accounting for most of the costs. Scarce resources should be allocated based on cost-effectiveness. High costs and low satisfaction with care suggest low-value care at EoL; however, there is little evidence regarding which patients receive such care. Objectives: To identify the characteristics of older patients who experience high-cost care but report low satisfaction with care at EoL. Design and methods: Secondary data analysis of mortality follow-back surveys: International Access, Rights, and Empowerment (IARE) studies. We surveyed the next of kin of older patients who received palliative care or died in hospital in England. Satisfaction with care at EoL and cost of hospital care calculated with quantity of services and unit costs. We used multinomial logistic regression to analyse factors associated with potentially low-value care. Results: 404 patients were included (mean [SD] age: 80.4 [8.5] years). During the last three months of life, 53.8% of the total hospital care costs were incurred by 20% of the patients. 36.6% of the respondents reported low satisfaction. Compared to patients with low-cost care and reporting satisfaction, patients who were 65-74 years old (relative risk ratio [RRR] = 3.2, 95% CI: 1.09 to 9.42), had low income (RRR = 4.12, 95% CI: 1.29 to 13.15) and with an illness duration of 1-12 months (RRR = 3.93, 95% CI: 1.37 to 11.21) were more likely to receive high-cost hospital care and report low satisfaction. Conclusions: Being younger, on low incomes and with short illness duration are associated with high-cost, low-satisfaction hospital care at EoL. Identifying underlying mechanisms may enable targeted interventions to reduce high-cost, low-value care. Further investigation is needed to change the care trajectories of patients with these risk factors.
- Open Access
- 5 June 2026
- Published by Springer Nature in Health Economics Review
The economics of decision-making in dementia care and related life-limiting illness: a narrative review
Background: Dementia represents a profound healthcare and economic challenge for the 21st century. A significant proportion of associated costs originate in decision-making between people with dementia, family carers, and health and social care practitioners. Economics is a decision science that may inform such choices, but the research evidence has not been collated and synthesised. We review the decision-making literature to analyse how economic insights can be applied to decision-making in life-limiting illness and identify findings applicable to dementia. Methods: Our literature search was comprehensive and included EconLit, Medline, Embase, and PsycInfo, as well as a targeted search of relevant economic literature. Results: We identified 9,854 studies, of which 62 were included. We found six key economic concepts: (a) principal-agent problem, (b) uncertainty, (c) asymmetric information, (d) hyperbolic discounting, (e) the empathy gap, and (f) non-linear value of time. These findings are helpful in understanding established patterns in the evidence base, including high end-of-life costs and variable efficacy of advance care planning. Discussion: These findings are used to consider the modifiability of formal, social, and household costs, and identify opportunities for future research. Dynamic communication between all decision-makers (patient, family, clinicians) is essential to overcome the identified barriers and drive improvements in dementia care. Further, we note that by integrating economic insights with lived experience, health sciences researchers get a better understanding of how decisions are made. Conclusion: Examining the dynamics that shape individual-level decision-making promotes a better understanding of the drivers of costs in life-limiting illness. Economics should make wider use of this methodological approach to examine decision-making in dementia care.
- 5 June 2026
- Published by Springer Nature in Health Economics Review
Open AccessThe economics of decision-making in dementia care and related life-limiting illness: a narrative review
Background: Dementia represents a profound healthcare and economic challenge for the 21st century. A significant proportion of associated costs originate in decision-making between people with dementia, family carers, and health and social care practitioners. Economics is a decision science that may inform such choices, but the research evidence has not been collated and synthesised. We review the decision-making literature to analyse how economic insights can be applied to decision-making in life-limiting illness and identify findings applicable to dementia. Methods: Our literature search was comprehensive and included EconLit, Medline, Embase, and PsycInfo, as well as a targeted search of relevant economic literature. Results: We identified 9,854 studies, of which 62 were included. We found six key economic concepts: (a) principal-agent problem, (b) uncertainty, (c) asymmetric information, (d) hyperbolic discounting, (e) the empathy gap, and (f) non-linear value of time. These findings are helpful in understanding established patterns in the evidence base, including high end-of-life costs and variable efficacy of advance care planning. Discussion: These findings are used to consider the modifiability of formal, social, and household costs, and identify opportunities for future research. Dynamic communication between all decision-makers (patient, family, clinicians) is essential to overcome the identified barriers and drive improvements in dementia care. Further, we note that by integrating economic insights with lived experience, health sciences researchers get a better understanding of how decisions are made. Conclusion: Examining the dynamics that shape individual-level decision-making promotes a better understanding of the drivers of costs in life-limiting illness. Economics should make wider use of this methodological approach to examine decision-making in dementia care.
- Open Access
- 21 April 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (5) , 644-654
Exploring engagement with a web-based self-directed psychoeducational program for advanced cancer patients and their caregivers (iFOCUS): A sub study analysis of the DIAdIC trial
Background: Supporting psychoeducational functioning for advanced cancer patients and informal caregivers (dyads) can be challenging. Self-managed digital interventions offer a possible cost-effective alternative but often face low engagement. Aim: To examine engagement with the iFOCUS intervention and to understand why it failed to improve the expected outcomes. Design: iFOCUS, a four-session digital self-managed 12-week intervention for dyads, was tested in six European countries as part of a randomized controlled trial. However, it showed no effects on outcomes. Using process evaluation data with 121 dyads, measures of engagement were examined to identify how engagement predicts dropout and to identify associations with patient/caregiver characteristics, post-intervention outcomes, and patient/caregiver evaluation of the intervention. Results: Measures of engagement showed variation in associations with participant characteristics. Lower engagement with the intervention among dyads at the outset, was associated with greater odds of dropout and engagement with the intervention decreased as the dyads progressed. Patients’ level of education and caregivers’ baseline emotional function, self-efficacy, dyadic coping, and knowledge of cancer were associated with engagement. However, there was no consistent evidence that engagement was associated with outcomes or evaluation of the intervention. Discussion: While we identified several associations between engagement and patient/caregiver characteristics, there were inconsistencies in the extent and nature of the associations, with more evidence that baseline characteristics impacted engagement, than evidence that engagement impacted on outcomes. However, using multiple measures of engagement did provide additional insights. A key recommendation from this study is the need for consideration of assessments of engagement for digital interventions.
- 21 April 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (5) , 644-654
Open AccessExploring engagement with a web-based self-directed psychoeducational program for advanced cancer patients and their caregivers (iFOCUS): A sub study analysis of the DIAdIC trial
Background: Supporting psychoeducational functioning for advanced cancer patients and informal caregivers (dyads) can be challenging. Self-managed digital interventions offer a possible cost-effective alternative but often face low engagement. Aim: To examine engagement with the iFOCUS intervention and to understand why it failed to improve the expected outcomes. Design: iFOCUS, a four-session digital self-managed 12-week intervention for dyads, was tested in six European countries as part of a randomized controlled trial. However, it showed no effects on outcomes. Using process evaluation data with 121 dyads, measures of engagement were examined to identify how engagement predicts dropout and to identify associations with patient/caregiver characteristics, post-intervention outcomes, and patient/caregiver evaluation of the intervention. Results: Measures of engagement showed variation in associations with participant characteristics. Lower engagement with the intervention among dyads at the outset, was associated with greater odds of dropout and engagement with the intervention decreased as the dyads progressed. Patients’ level of education and caregivers’ baseline emotional function, self-efficacy, dyadic coping, and knowledge of cancer were associated with engagement. However, there was no consistent evidence that engagement was associated with outcomes or evaluation of the intervention. Discussion: While we identified several associations between engagement and patient/caregiver characteristics, there were inconsistencies in the extent and nature of the associations, with more evidence that baseline characteristics impacted engagement, than evidence that engagement impacted on outcomes. However, using multiple measures of engagement did provide additional insights. A key recommendation from this study is the need for consideration of assessments of engagement for digital interventions.
- Open Access
- 18 March 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (6) , 744-756
Unequal ends: A systematic review comparing place of death in rural, coastal and urban areas for older people with dementia to cancer
Background: Despite the growing older population with increased chronic conditions in rural and coastal areas, it is currently unclear how location impacts where people die. Aim: To compare where people with dementia and people with cancer die across rural, coastal and urban areas, and examine associated factors. Design: A systematic review reported in accordance with PRISMA guidelines. Data sources: MEDLINE, PsycINFO, CINAHL, Embase and ASSIA databases were searched 2005–November 2024. Results: Twenty-nine studies were included. Fifteen studies compared rural and urban populations, eleven urban only, two coastal urban and one rural. No studies considered the coastal context when examining place of death. 6,988,050 cancer and 3,517,909 dementia decedents were included across seventeen cancer studies, nine dementia, and three both. All studies were rated high quality. Rural, dementia decedents were more likely to die in residential care than urban residents, who were more likely to die in hospital. Large studies of cancer populations found trends towards home deaths for rural residents and hospital for urban, but this was inconsistent across countries. Thirteen studies reported factors associated with place of death for people with cancer, compared to four dementia. Discussion: Hospital deaths appear more common in urban areas, with more home/care home deaths in rural areas. Coastal patterns are poorly described. Better understanding how these locations are associated with place of death, especially for people with dementia, is needed to guide more equitable, efficient service planning. Further work on associated factors will support a nuanced understanding of drivers of place of death.
- 18 March 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (6) , 744-756
Open AccessUnequal ends: A systematic review comparing place of death in rural, coastal and urban areas for older people with dementia to cancer
Background: Despite the growing older population with increased chronic conditions in rural and coastal areas, it is currently unclear how location impacts where people die. Aim: To compare where people with dementia and people with cancer die across rural, coastal and urban areas, and examine associated factors. Design: A systematic review reported in accordance with PRISMA guidelines. Data sources: MEDLINE, PsycINFO, CINAHL, Embase and ASSIA databases were searched 2005–November 2024. Results: Twenty-nine studies were included. Fifteen studies compared rural and urban populations, eleven urban only, two coastal urban and one rural. No studies considered the coastal context when examining place of death. 6,988,050 cancer and 3,517,909 dementia decedents were included across seventeen cancer studies, nine dementia, and three both. All studies were rated high quality. Rural, dementia decedents were more likely to die in residential care than urban residents, who were more likely to die in hospital. Large studies of cancer populations found trends towards home deaths for rural residents and hospital for urban, but this was inconsistent across countries. Thirteen studies reported factors associated with place of death for people with cancer, compared to four dementia. Discussion: Hospital deaths appear more common in urban areas, with more home/care home deaths in rural areas. Coastal patterns are poorly described. Better understanding how these locations are associated with place of death, especially for people with dementia, is needed to guide more equitable, efficient service planning. Further work on associated factors will support a nuanced understanding of drivers of place of death.
- Open Access
- 4 March 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (7) , 908-917
Specialist palliative care improves patient experience, reduces bed days and saves money: An economic modelling study of home- and hospital-based care
Background: High-quality evidence suggests that specialist palliative care reduces the odds of dying in hospital. The economic implications have not been established. Aim: To evaluate the cost-effectiveness of home- and hospital-based specialist palliative care for adults with poor prognosis in England. Design: Health-economic decision-modelling using five-state Markov cohort models with a 24-h cycle and lifetime horizon. Setting/participants: We evaluated home- and hospital-based care separately. We modelled counterfactuals using Cochrane review evidence of treatment effects on place of death and quality of life. We estimated place of death distributions, utilisation, quality-adjusted life years, and unit and intervention costs from the literature. Results: Home-based care was associated with reduced costs of £7908 per person (95% confidence interval: −18,044 to 395) and increased quality-adjusted life years by 0.035 per person (0.033 to 0.037). Hospital-based care reduced costs by £6480 per person (−11,482 to −1671) and increased quality-adjusted life years by 0.033 per person (0.031 to 0.035). We estimated that for England in 2022, specialist palliative care supported over 20,000 people to die outside of hospital, saved approximately 1.5 million hospital bed days and reduced system expenditures by £817 million. Conclusion: Specialist palliative care reduces hospital bed days, deaths in hospital and healthcare costs, as well as improving quality of life, among adults in England. A minority who might benefit currently receive specialist palliative care and needs are growing rapidly. Expanding access may yield further gains, but bridging current gaps in access also requires new approaches to reaching and meeting the needs of underserved groups.
- 4 March 2026
- Published by SAGE Publications in Palliative Medicine
- Vol. 40 (7) , 908-917
Open AccessSpecialist palliative care improves patient experience, reduces bed days and saves money: An economic modelling study of home- and hospital-based care
Background: High-quality evidence suggests that specialist palliative care reduces the odds of dying in hospital. The economic implications have not been established. Aim: To evaluate the cost-effectiveness of home- and hospital-based specialist palliative care for adults with poor prognosis in England. Design: Health-economic decision-modelling using five-state Markov cohort models with a 24-h cycle and lifetime horizon. Setting/participants: We evaluated home- and hospital-based care separately. We modelled counterfactuals using Cochrane review evidence of treatment effects on place of death and quality of life. We estimated place of death distributions, utilisation, quality-adjusted life years, and unit and intervention costs from the literature. Results: Home-based care was associated with reduced costs of £7908 per person (95% confidence interval: −18,044 to 395) and increased quality-adjusted life years by 0.035 per person (0.033 to 0.037). Hospital-based care reduced costs by £6480 per person (−11,482 to −1671) and increased quality-adjusted life years by 0.033 per person (0.031 to 0.035). We estimated that for England in 2022, specialist palliative care supported over 20,000 people to die outside of hospital, saved approximately 1.5 million hospital bed days and reduced system expenditures by £817 million. Conclusion: Specialist palliative care reduces hospital bed days, deaths in hospital and healthcare costs, as well as improving quality of life, among adults in England. A minority who might benefit currently receive specialist palliative care and needs are growing rapidly. Expanding access may yield further gains, but bridging current gaps in access also requires new approaches to reaching and meeting the needs of underserved groups.
- Open Access
- 21 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 162, 108240
Assessing the cost-effectiveness of two psychoeducational interventions for people with cancer and their caregivers: An economic evaluation of the multi-country DIAdIC trial
- 21 January 2026
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 162, 108240
Open AccessAssessing the cost-effectiveness of two psychoeducational interventions for people with cancer and their caregivers: An economic evaluation of the multi-country DIAdIC trial
- Open Access
- 21 November 2025
- Published by Wiley in HIV Medicine
- Vol. 27 (2) , 283-298
Comprehensive geriatric assessment for people living with HIV and frailty: A mixed‐methods feasibility randomized controlled trial
Objective: Prevalence of geriatric syndromes including frailty among people living with HIV is increasing and at younger ages. There is no gold standard model of care for people with HIV and frailty. This study aimed to determine the acceptability of a comprehensive geriatric assessment and management plan, delivered jointly by a geriatrician and HIV physician (the Silver Clinic) in outpatient HIV services, and also the feasibility of conducting a randomized controlled trial (RCT) of the Silver Clinic compared with standard care. Design: Mixed‐methods single‐centre, parallel, two‐arm feasibility RCT. Methods: People living with HIV ≥50 years old, who screened as frail using the FRAIL scale were randomized to: usual care or the Silver Clinic. Randomization was stratified by age and sex, target N = 84. The primary objective was to determine whether a definitive trial is feasible. Results: Twenty‐five participants (46% of n = 55 eligible patients) were randomized. One hundred percent of participants attended their 6‐month follow‐up and 91% at 12 months. More than 90% of the outcome measures were completed at all time points. Interviews revealed study processes and outcome measures were acceptable, and that the intervention was valued by people living with HIV and frailty. Conclusions: Delivering a comprehensive geriatric assessment jointly by a geriatrician and HIV physician was feasible and acceptable. Retention and completion of outcome measures were high, although recruiting sufficient frail individuals from one site was challenging. A RCT to determine the effectiveness of the Silver Clinic is warranted, but will require a multicentre design and an extended recruitment period to address recruitment challenges.
- 21 November 2025
- Published by Wiley in HIV Medicine
- Vol. 27 (2) , 283-298
Open AccessComprehensive geriatric assessment for people living with HIV and frailty: A mixed‐methods feasibility randomized controlled trial
Objective: Prevalence of geriatric syndromes including frailty among people living with HIV is increasing and at younger ages. There is no gold standard model of care for people with HIV and frailty. This study aimed to determine the acceptability of a comprehensive geriatric assessment and management plan, delivered jointly by a geriatrician and HIV physician (the Silver Clinic) in outpatient HIV services, and also the feasibility of conducting a randomized controlled trial (RCT) of the Silver Clinic compared with standard care. Design: Mixed‐methods single‐centre, parallel, two‐arm feasibility RCT. Methods: People living with HIV ≥50 years old, who screened as frail using the FRAIL scale were randomized to: usual care or the Silver Clinic. Randomization was stratified by age and sex, target N = 84. The primary objective was to determine whether a definitive trial is feasible. Results: Twenty‐five participants (46% of n = 55 eligible patients) were randomized. One hundred percent of participants attended their 6‐month follow‐up and 91% at 12 months. More than 90% of the outcome measures were completed at all time points. Interviews revealed study processes and outcome measures were acceptable, and that the intervention was valued by people living with HIV and frailty. Conclusions: Delivering a comprehensive geriatric assessment jointly by a geriatrician and HIV physician was feasible and acceptable. Retention and completion of outcome measures were high, although recruiting sufficient frail individuals from one site was challenging. A RCT to determine the effectiveness of the Silver Clinic is warranted, but will require a multicentre design and an extended recruitment period to address recruitment challenges.
- Open Access
- 4 November 2025
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
The cost of drug repurposing: parallel economic evaluation of mirtazapine for severe breathlessness in the multinational BETTER-B trial
Background: Breathlessness is a prevalent, distressing symptom in advanced respiratory disease. Proven treatments are lacking. Mirtazapine, an antidepressant, is increasingly prescribed. The placebo-controlled BETTER-B trial did not find significant clinical benefit of mirtazapine for severe breathlessness, and patient experiences were mixed. Given mirtazapine’s low cost and wide availability, it is important to understand effects more broadly. Methods: We conducted a parallel cost-effectiveness analysis of mirtazapine versus placebo. BETTER-B recruited 225 adults with chronic obstructive pulmonary disease and/or Interstitial Lung Diseases in seven countries between 2021 and 2023. We calculated quality-adjusted life years (QALYs) using EuroQoL EQ-5D-5 L and national value sets, and combined self-reported healthcare and informal care frequencies with unit costs. Primary trial endpoint was at day 56, with sensitivity analysis at day 180 (trial exit). Findings: In primary analysis mirtazapine reduced QALYs (-0.006 (95% confidence interval (CI): -0.012 to -0.001)) and was associated with higher total costs (+€231 (95% CI: -218 to + 680)). For willingness-to-pay thresholds of €20,000-€40,000 per QALY, mirtazapine had a 1%-2% likelihood of being cost-effective. These findings were substantively unaffected by sensitivity analyses to timeframe, perspective, outcome measurement, and modelling strategy. Interpretation: Repurposing mirtazapine to treat severe breathlessness negatively impacted patient outcomes while being associated with higher formal and informal costs, and should be discouraged. Off-label prescribing of repurposed medicines without robust evidence risks unnecessary strain on healthcare systems and families. Economic evaluation within testing of repurposed medicines is important. Parallel cost-effectiveness analyses can deliver high-value information even when the efficacy trial finds no effect.
- 4 November 2025
- Published by Springer Nature in BMC Health Services Research
- Vol. 25 (1) , 1-11
Open AccessThe cost of drug repurposing: parallel economic evaluation of mirtazapine for severe breathlessness in the multinational BETTER-B trial
Background: Breathlessness is a prevalent, distressing symptom in advanced respiratory disease. Proven treatments are lacking. Mirtazapine, an antidepressant, is increasingly prescribed. The placebo-controlled BETTER-B trial did not find significant clinical benefit of mirtazapine for severe breathlessness, and patient experiences were mixed. Given mirtazapine’s low cost and wide availability, it is important to understand effects more broadly. Methods: We conducted a parallel cost-effectiveness analysis of mirtazapine versus placebo. BETTER-B recruited 225 adults with chronic obstructive pulmonary disease and/or Interstitial Lung Diseases in seven countries between 2021 and 2023. We calculated quality-adjusted life years (QALYs) using EuroQoL EQ-5D-5 L and national value sets, and combined self-reported healthcare and informal care frequencies with unit costs. Primary trial endpoint was at day 56, with sensitivity analysis at day 180 (trial exit). Findings: In primary analysis mirtazapine reduced QALYs (-0.006 (95% confidence interval (CI): -0.012 to -0.001)) and was associated with higher total costs (+€231 (95% CI: -218 to + 680)). For willingness-to-pay thresholds of €20,000-€40,000 per QALY, mirtazapine had a 1%-2% likelihood of being cost-effective. These findings were substantively unaffected by sensitivity analyses to timeframe, perspective, outcome measurement, and modelling strategy. Interpretation: Repurposing mirtazapine to treat severe breathlessness negatively impacted patient outcomes while being associated with higher formal and informal costs, and should be discouraged. Off-label prescribing of repurposed medicines without robust evidence risks unnecessary strain on healthcare systems and families. Economic evaluation within testing of repurposed medicines is important. Parallel cost-effectiveness analyses can deliver high-value information even when the efficacy trial finds no effect.
- Open Access
- 24 October 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (763) , e116-e123
Continuity of primary care and end-of-life care costs in dementia: a retrospective cohort study
Background: End-of-life dementia care costs are expected to rise as populations age. Higher continuity of care with GPs is associated with reduced hospital admissions at the end of life, but the impact on costs is not known. Aim: To explore the association of continuity of primary care on hospital and general practice costs in the last year of life among people with dementia. Design and setting: A retrospective cohort study using a primary care dataset linked with national hospital and mortality records. Adults (aged >18 years) who died in England between 2009 and 2018 with a diagnosis of dementia were included. Method: The Continuity of Care Index (COCI) of GP contacts in the last year of life was calculated, which measures patterns of care across GPs. Hospital and general practice costs were calculated using average national tariffs. Costs were modelled using a multivariable generalised linear model, estimating the average marginal effect of perfect continuity over non-continuity of care. Results: In total, 32 799 people were included. The mean age at death was 86.60 years (standard deviation [SD] 8.04 years), 64.2% ( n = 21 057) were female, and 56.6% ( n = 18 556) lived in care homes before death. The average COCI score was 0.38 (SD 0.25). People with perfect continuity had on average £2097 (95% confidence interval = 1319 to 2875) lower total costs in the last year than those with non-continuity of care. Conclusion: Continuity of care with GPs is associated with lower total costs and might contribute to reduce hospital admissions and costs among people with dementia in their last year of life.
- 24 October 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (763) , e116-e123
Open AccessContinuity of primary care and end-of-life care costs in dementia: a retrospective cohort study
Background: End-of-life dementia care costs are expected to rise as populations age. Higher continuity of care with GPs is associated with reduced hospital admissions at the end of life, but the impact on costs is not known. Aim: To explore the association of continuity of primary care on hospital and general practice costs in the last year of life among people with dementia. Design and setting: A retrospective cohort study using a primary care dataset linked with national hospital and mortality records. Adults (aged >18 years) who died in England between 2009 and 2018 with a diagnosis of dementia were included. Method: The Continuity of Care Index (COCI) of GP contacts in the last year of life was calculated, which measures patterns of care across GPs. Hospital and general practice costs were calculated using average national tariffs. Costs were modelled using a multivariable generalised linear model, estimating the average marginal effect of perfect continuity over non-continuity of care. Results: In total, 32 799 people were included. The mean age at death was 86.60 years (standard deviation [SD] 8.04 years), 64.2% ( n = 21 057) were female, and 56.6% ( n = 18 556) lived in care homes before death. The average COCI score was 0.38 (SD 0.25). People with perfect continuity had on average £2097 (95% confidence interval = 1319 to 2875) lower total costs in the last year than those with non-continuity of care. Conclusion: Continuity of care with GPs is associated with lower total costs and might contribute to reduce hospital admissions and costs among people with dementia in their last year of life.
- Open Access
- 22 September 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (1) , e69-e81
Economic Benefits of Investment in Palliative Care: An Appraisal of Current Evidence and Call to Action
- 22 September 2025
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 71 (1) , e69-e81
Open AccessEconomic Benefits of Investment in Palliative Care: An Appraisal of Current Evidence and Call to Action